Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...
FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...
Business Insider on MSN6d
See ya, knock-off OzempicLots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
Novo sells semaglutide as Ozempic, Rybelsus and Wegovy. The CMS will treat the different forms as a single product in price ...
GetSimpli Oral Tirzepatide is competitively priced, making it an accessible option for those seeking effective weight loss and metabolic health solutions. The regular price is $349.00, but first ...
H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Lexaria Bioscience (LEXX) to $7 from $10 and keeps a Buy rating on the ...
Eli Lilly markets its tirzepatide medicines, Mounjaro for T2D and Zepbound for obesity, which competes with NVO’s Ozempic and Wegovy. The fall in LLY’s stock price is likely because investors ...
Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback